CARGO THERAPEUTICS, INC.
CARGO THERAPEUTICS, INC.
SAN CARLOS, CA
Loading...
Price History
Market Data
| Market Cap | - |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | -4.64 |
| Dividend Yield | - |
| D/E Ratio | 0.09 |
| Current Ratio | 12.37 |
| Currency | USD |
Key Financial Metrics
-
Revenue
-221.78M
Net Income
-4.64
EPS (Diluted)
-297.82M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-238.57M
Returns & Efficiency
Return on Assets (ROA)
-85.8%
Return on Equity (ROE)
-93.3%
Dividend Yield
-
EPS
-4.64
Financial Health
Total Assets
258.61M
Total Debt
-
Debt to Equity
0.09x
Current Ratio
12.37
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | SAN CARLOS, CA |
| Fiscal Year | 2024 |
Peers
AMGEN INC
AMGN
177.13B
P/E: --
GILEAD SCIENCES INC
GILD
166.13B
P/E: --
166.13B
P/E: --
BIOGEN IDEC INC.
BIIB
27.90B
P/E: --
BIOGEN INC.
BIIB
27.90B
P/E: --
19.11B
P/E: --
MODERNA, INC.
MRNA
18.38B
P/E: --
Moderna, Inc.
MRNA
18.38B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap-
P/E Ratio (TTM)-
Price to Book-
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-93.3%
ROA-85.8%
Leverage & Liquidity
Debt to Equity0.09
Current Ratio12.37
Total Debt-
Total Assets$258.61M
Stockholders' Equity$237.70M
Income Statement (FY 2024)
Revenue-
Gross Profit-
Operating Income$-238.57M
Net Income$-221.78M
EPS (Diluted)$-4.64
Cash Flow (FY 2024)
Free Cash Flow$-297.82M
Cash & Equivalents$107.75M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 835 INDUSTRIAL ROAD, SUITE 400 SAN CARLOS, CA 94070 |
| Phone | 650-499-8950 |
| Incorporated | DE, US |
| EIN | 844080422 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 48.13M |
| Stockholders' Equity | $237.70M |
| Cash & Equivalents | $107.75M |
Recent Filings
View All
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-06
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-08
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-29
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2025-03-12
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-11-12
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-08-12
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-05-14
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2024-04-24
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2024-03-21
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2023-12-13
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | CARGO THERAPEUTICS, INC. |
| Ticker | None |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | SAN CARLOS, CA |
| Fiscal Year | 2024 |
Financial Summary
| Market Cap | - |
| Revenue | - |
| Net Income | -221.78M |
| P/E Ratio | - |
| EPS | -4.64 |
| Net Margin | - |
| ROE | -93.3% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...